Prescrire examined the packaging of 190 medicinal products in 2021. The results were mixed, with a few signs of progress alongside persistent or recurrent flaws. A marked difference was seen between products authorised through the European centralised procedure and those authorised through the French national procedure, with the international nonproprietary name (INN) all too often printed indistinctly on the boxes of the latter, overshadowed by the more prominent brand name. The box of some medicinal products is printed with useful information for patients on how to take the drug properly, helping to inform patients about theirtreatmentfrom the moment it is dispensed. In a few exceptional cases, tablets or capsules previously marketed in bulk bottles were upgraded to unit-dose blister packaging. Pre-cut unit-dose blister packaging was unfortunately rare among recently authorised products.
展开▼
